

# PDA Aseptic Manufacturing Excellence Conference 2025

## Agenda

**Monday, 13 October**

AEDT Daylight Time (UTC +11:00)

08:00 – 08:45	<b>Registration</b>
<b>Opening Plenary – Advancing Excellence in Aseptic Manufacture</b>	
08:45 – 10:30	<p><b>Welcome &amp; Opening Remarks</b></p> <p>08:45 – 08:55 • <b>Justine D. Mann MBA, BSc</b>, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i></p>
	<p><b>Adoption of PIC/S PE009-17</b></p> <p>08:55 – 09:25 • <b>Matt Davis</b> , Director, Inspections Section - Manufacturing Quality Branch, <i>Therapeutic Goods Administration</i></p>
	<p><b>'Designing the State of Control' within the Contamination Control Strategy (CCS)</b></p> <p>09:25 – 09:55 • <b>Tracy Moore</b> , CEO, <i>TM Pharma Group</i></p>
	<p>09:55 – 10:30 <b>Panel Discussion and Q&amp;A</b></p>
10:30 – 11:10	<b>Coffee Break</b>
<b>Session 1- Innovative Tools &amp; Processes to Assure Sterility and Quality</b>	
11:10 – 12:35	<p><b>Welcome Remarks</b></p> <p>11:10 – 11:15 • <b>Mylinh La PhD</b>, Senior Laboratory Manager, <i>CSIRO</i></p>
	<p><b>Risk Based Approach for Design of Environmental Monitoring Programmes</b></p> <p>11:15 – 11:40 • <b>Kelly Waldron PhD</b>, Business Unit Manager, Quality and Manufacturing Science Consulting, <i>ValSource, Inc.</i></p>
	<p><b>Rapid Micro - Real-world challenges – and solutions – for the use of biofluorescent particle counters in Grade A aseptic filling applications</b></p> <p>11:40 – 12:05 • <b>Brent N. Lieffers</b> , Senior Director, Innovation Advocacy, <i>Cytiva</i></p>
	<p>12:05 – 12:20 <b>Q&amp;A</b></p>
<b>Product Demo by CAI</b>	
12:20 – 12:35	<p><b>Bridging the Gap from Project Mode to Sustained Operations</b></p> <p>12:20 – 12:35 • <b>Lewis O'Brien</b> , Country Manager-Australia &amp; New Zealand, <i>CAI</i></p>
12:35 – 13:35	<b>Lunch Break</b>

## Session 2- Sustaining & Maintaining Quality in Aseptic Manufacture

### Welcome Remarks

- 13:35 – 13:40
- **Micheal Schafferius** , Application Specialist for Filtration and Quality, *Sartorius Stedim Biotech Australia*

### Developing a CCS (Contamination Control Strategy) for ATMP Cleanrooms

- 13:40 – 14:05
- **James N. Polarine MA**, Principal Consultant, *STERIS*

### Sterility Assurance – Recent PDA publications to guide alignment with PIC/S Annex 1 Implementation

- 14:05 – 14:30
- **Bruce Loxley** , Science Advisory Board member 2022-2028, *PDA*

### Navigating Quality and Compliance in a Biologics CDMO

- 14:30 – 14:55
- **Melissa El Khouri** , Head of Quality, *BioCina Adelaide*

14:55 – 15:10 **Q&A**

15:10 – 15:50 **Coffee Break**

## Session 3 - Concurrent A: Case Studies in Quality and Compliance Across Aseptic Manufacturing

### Welcome Remarks

- 15:50 – 15:55
- **Nadia Seidel** , Site Operational Excellence Lead, *Pfizer*

### Challenges and Opportunities in Radiopharmaceutical Manufacturing

- 15:55 – 16:20
- **Robert Raposio Ph.D., MMgt**, Process Performance Manager, *ANSTO Nuclear Medicine*

### Case Study - Operational Readiness- A Practical Approach

- 16:20 – 16:35
- **Christopher Cassidy** , Operational Readiness Director, *Pfizer*

### Case Study - Risk Based Qualification of Facilities in Practice

- 16:35 – 16:50
- **Samuel O'Callaghan** , Managing Director - Australia & New Zealand, *PSC Biotech*

16:50 – 17:05 **Q&A**

17:05 – 17:10 **Closing Remarks**

## Session 3 - Concurrent B: GMP Compliance and Quality Assurance in Veterinary Sterile Products

### Welcome Remarks

- 15:50 – 15:55
- **Justine D. Mann MBA, BSc**, Chief Executive Officer, CBE Pure Solutions, *President, PDA Australia Chapter*

### GMP Changes

- 15:55 – 16:20
- **Malcom Hammond** , Director, Manufacturing Quality and Licensing & Assurance, *Australian Pesticides and Veterinary Medicines Authority (APVMA)*

### Aseptic Manufacture & the APVMA Code: Meeting Today's Standards, Shaping Tomorrow's Compliance

- 16:20 – 16:45
- **Louise White** , APVMA Auditor, Director and Consultant, *SeerPharma Pty Ltd*

<b>QRM Basics</b>	
16:45 – 17:10	<ul style="list-style-type: none"><li>• <b>Kelly Waldron PhD</b>, Business Unit Manager, Quality and Manufacturing Science Consulting, <i>ValSource, Inc.</i></li></ul>
17:10 – 17:25	<b>Q&amp;A</b>
<b>Closing Remarks</b>	
17:25 – 17:30	<ul style="list-style-type: none"><li>• <b>Justine D. Mann MBA, BSc</b>, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i></li></ul>
17:10 – 19:10	<b>Networking Reception</b>

## Tuesday, 14 October

AEDT Daylight Time (UTC +11:00)

07:30 – 08:45	Registration		
07:45 – 08:45	Breakfast Session (Part 1)		
	07:45 – 08:45	How to Use Lifecycle Risk Assessments to Improve Quality and Operational Processes <ul style="list-style-type: none"><li>Kelly Waldron PhD, Business Unit Manager, Quality and Manufacturing Science Consulting, ValSource, Inc.</li></ul>	
08:45 – 09:00	Break		
09:00 – 09:15	Breakfast Session (Part 2)		
	09:00 – 09:15	Welcome to Day 2 - updates from the PDA Australia Chapter and Global PDA Network <ul style="list-style-type: none"><li>Justine D. Mann MBA, BSc, Chief Executive Officer, CBE Pure Solutions, President, PDA Australia Chapter</li><li>Sadman Bhuiyan , Project Manager, Scientist and Educator, INOVIQ Ltd.</li></ul>	
09:15 – 10:25	Session 4- Sterile Container Innovations: Meeting Annex 1 Expectations with Confidence		
	09:15 – 09:20	Welcome Remarks <ul style="list-style-type: none"><li>Sadman Bhuiyan , Project Manager, Scientist and Educator, INOVIQ Ltd.</li></ul>	
	09:20 – 09:45	Implementation of Annex 1 by Primary Packaging Suppliers: A Case Study for Improved Compliance via Advanced Particle Control and Reduced Interventions <ul style="list-style-type: none"><li>Colleen O'Brien MS, Strategy and Technical Affairs, Gerresheimer</li></ul>	
	09:45 – 10:10	A Practical Road Map for Compliance to the Container Closure Requirements in the EU GMP Annex 1 <ul style="list-style-type: none"><li>Derek I. Duncan PhD, Director Product Lines, LIGHTHOUSE Instruments</li></ul>	
	10:10 – 10:25	Panel Discussion and Q&A	
10:25 – 11:00	Coffee Break		
Session 5- Maintaining a State of Control: Strategies for Robust Aseptic Processing			
	Welcome Remarks		

11:00 – 12:35	11:00 – 11:05	<ul style="list-style-type: none"> <li>• <b>Jo Sherriff</b> , Engineering Compliance Manager, <i>SeerPharma Pty. Ltd.</i></li> </ul>
	11:05 – 11:30	<b>Cleaning Classified Rooms to meet EU Annex 1 requirements</b> <ul style="list-style-type: none"> <li>• <b>James N. Polarine MA</b>, Principal Consultant, <i>STERIS</i></li> </ul>
	11:30 – 11:55	<b>GMP Myth Busting</b> <ul style="list-style-type: none"> <li>• <b>Brent N. Loeffers</b> , Senior Director, Innovation Advocacy, <i>Cytiva</i></li> </ul>
	11:55 – 12:20	<b>Aseptic Processing – Emerging expectations or a paradigm shift?</b> <ul style="list-style-type: none"> <li>• <b>Bruce Loxley</b> , Science Advisory Board member 2022-2028, <i>PDA</i></li> </ul>
	12:20 – 12:35	<b>Panel Discussion and Q&amp;A</b>
12:35 – 13:35	<b>Lunch Break</b>	
13:35 – 14:50	<b>Session 6- QC Innovation Spotlight: Case Studies in Advanced Testing for Sterility Assurance</b>	
	13:35 – 13:40	<b>Welcome Remarks</b> <ul style="list-style-type: none"> <li>• <b>Craig Stephens</b> , Global Head of Quality Control Operations, <i>CSL</i></li> </ul>
	13:40 – 13:55	<b>Case Study - Optimisation of Mycoplasma Testing using BioFire</b> <ul style="list-style-type: none"> <li>• <b>Melissa Damino</b> , Director of Quality Control, Tullamarine, <i>CSL Seqirus</i></li> </ul>
	13:55 – 14:10	<b>Case Study - rFC Endotoxin Testing</b> <ul style="list-style-type: none"> <li>• <b>Robyn Hofer</b> , Operations Manager, <i>CBE Pure Solutions</i></li> </ul>
	14:10 – 14:25	<b>Case Study - Implementation of Automated EM Plate Reader</b> <ul style="list-style-type: none"> <li>• <b>Mark Gracie</b> , LTS Manager, <i>Pfizer</i></li> </ul>
	14:25 – 14:50	<b>Q&amp;A</b>
14:50 – 15:30	<b>Coffee Break</b>	
15:30 – 17:10	<b>Closing Plenary - Annex 1 Hot Topics: Paradigm Shifts and GMPs for the 21st Century</b>	
	15:30 – 15:35	<b>Welcome Remarks</b> <ul style="list-style-type: none"> <li>• <b>Lisa Bennett MSc</b>, Director, <i>LB Consulting Australia Pty Ltd</i></li> </ul>
	15:35 – 16:00	<b>PUPSIT - risk considerations and compliance</b> <ul style="list-style-type: none"> <li>• <b>Matt Davis</b> , Director, Inspections Section - Manufacturing Quality Branch, <i>Therapeutic Goods Administration</i></li> </ul>
	16:00 – 16:10	<b>Introduction to the Panel Discussion</b> <ul style="list-style-type: none"> <li>• <b>Lisa Bennett MSc</b>, Director, <i>LB Consulting Australia Pty Ltd</i></li> </ul>
	<b>Expert Panel Discussion and Q&amp;A</b> <ul style="list-style-type: none"> <li>• <b>Tracy Moore</b> , CEO, <i>TM Pharma Group</i></li> <li>• <b>Matt Davis</b> , Director, Inspections Section - Manufacturing Quality Branch, <i>Therapeutic Goods Administration</i></li> </ul>	

	<div>16:10 – 17:00</div> <ul style="list-style-type: none"><li>• <b>Brent N. Lieffers</b> , Senior Director, Innovation Advocacy, <i>Cytiva</i></li><li>• <b>James N. Polarine MA</b>, Principal Consultant, <i>STERIS</i></li><li>• <b>Malcom Hammond</b> , Director, Manufacturing Quality and Licensing &amp; Assurance, <i>Australian Pesticides and Veterinary Medicines Authority (APVMA)</i></li></ul>
<div>17:00 – 17:10</div>	<div><b>Closing Remarks</b></div> <div><b>Justine D. Mann MBA, BSc</b>, Chief Executive Officer, CBE Pure Solutions, <i>President, PDA Australia Chapter</i></div>